熱門資訊> 正文

Emergent Biotolions为CYFENDUS授予3000万美元的合同修改权

2025-09-02 20:08

Emergent BioSolutions (NYSE:EBS) has received a $30 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (OTCPK:ASPR) within the U.S. Department of Health and Human Services (HHS) to supply CYFENDUS.
Deliveries are expected to begin this calendar year and are scheduled to be completed by March 2026.
EBS +1.20% premarket to $8.4.
Source: Press Release

More on Emergent Biosolutions

Emergent BioSolutions: Q2 Results Could Spark A Strong 2025 Rally
Emergent BioSolutions Inc. (EBS) Q2 2025 Earnings Call Transcript
Emergent BioSolutions: Strategic Turnaround Proving Tricky, But I'm Still Hopeful
Emergent Biosolutions Q2 2025 Earnings Preview
Emergent BioSolutions signs contract modification award for CNJ-016

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。